Hims & Hers (NYSE: HIMS) has been on a wild journey over the past year as GLP-1s drive both big gains and big losses for the ...

Fintel reports that on January 10, 2025, Citigroup downgraded their outlook for Hims & Hers Health (NYSE:HIMS) from Neutral ...

Shares in Hims Hers Health Inc (NYSE:HIMS) fell Friday after Citigroup (NYSE:C) analysts downgraded the stock to Sell/High Risk, citing overvaluation concerns tied to its GLP-1 revenue stream.

Hims & Hers Health (HIMS) stock gained after Citi upgraded the company, while agilon health (AGL) stock slipped after its downgrade. Read more here.

Citi downgraded Hims & Hers to Sell from Neutral with a $25 price target Stay Ahead of the Market:Discover outperforming stocks and invest ...

Citi downgraded Hims & Hers to Sell from Neutral with a price target of $25, up from $24. The firm thinks the market is overvaluing the ...

Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) have been given a consensus recommendation of “Hold” by the ...

Teladoc's growth and profitability challenges continue amid rising competition. Learn why TDOC stock remains under pressure with future uncertainties.

Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees ...

When it comes to the efficacy of a hair loss treatment, there’s nothing more telling than a before and after photo.

March E-mini S&P futures (ESH25) are down -1.64%, and March E-mini Nasdaq futures (NQH25) are down -1.98%.  Stocks are selling off today, with the S&P 500 and the Dow Jones Industrials dropping to ...

Japan's Nikkei Stock 225 slid to a 2-week low and closed down -1.05%. March 10-year T-notes (ZNH25) Friday closed down -26.5 ticks.  The 10-year T-note yield rose +8.3 bp to 4.772%.  Mar T-notes ...